Inamura Kentaro
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Front Oncol. 2017 Aug 28;7:193. doi: 10.3389/fonc.2017.00193. eCollection 2017.
Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung cancer. The identification of driver genetic alterations and potential molecular targets has resulted in molecular-targeted therapies for an increasing number of lung cancer patients. Thus, the histopathological classification of lung cancer was modified in accordance with the increased understanding of molecular profiles. This review focuses on recent developments in the molecular profiling of lung cancer and provides perspectives on updated diagnostic concepts in the new 2015 WHO classification. The WHO classification will require additional revisions to allow for reliable, clinically meaningful tumor diagnoses as we gain a better understanding of the molecular characteristics of lung cancer.
由于诊断较晚且治疗干预措施有限,肺癌是全球癌症相关死亡的主要原因。最近,已确定了肺癌的综合分子特征。这些新特征加深了对肺癌分子病理学的理解。驱动基因改变和潜在分子靶点的鉴定已为越来越多的肺癌患者带来了分子靶向治疗。因此,肺癌的组织病理学分类根据对分子特征的进一步了解进行了修改。本综述重点关注肺癌分子分析的最新进展,并就2015年世界卫生组织(WHO)新分类中的更新诊断概念提供观点。随着我们对肺癌分子特征的进一步了解,WHO分类将需要进一步修订,以实现可靠的、具有临床意义的肿瘤诊断。